These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
73 related articles for article (PubMed ID: 1932374)
1. Plasma disappearance and organ distribution of recombinant human tumor necrosis factor-alpha in rats. Pang XP; Hershman JM; Pekary AE Lymphokine Cytokine Res; 1991 Aug; 10(4):301-6. PubMed ID: 1932374 [TBL] [Abstract][Full Text] [Related]
2. Pharmacokinetics and tissue distribution of recombinant human tumor necrosis factor-alpha in mice. Ferraiolo BL; Moore JA; Crase D; Gribling P; Wilking H; Baughman RA Drug Metab Dispos; 1988; 16(2):270-5. PubMed ID: 2898346 [TBL] [Abstract][Full Text] [Related]
3. Rapid and specific targeting of 125I-labeled B lymphocyte stimulator to lymphoid tissues and B cell tumors in mice. Riccobene TA; Miceli RC; Lincoln C; Knight Y; Meadows J; Stabin MG; Sung C J Nucl Med; 2003 Mar; 44(3):422-33. PubMed ID: 12621010 [TBL] [Abstract][Full Text] [Related]
4. Pharmacokinetics of tumor necrosis factor alpha after intravenous administration in rats. Dose dependence and influence of tumor necrosis factor beta. Zahn G; Greischel A Arzneimittelforschung; 1989 Sep; 39(9):1180-2. PubMed ID: 2590273 [TBL] [Abstract][Full Text] [Related]
5. Tissue distribution of recombinant human tumor necrosis factor alpha derivative in mice. Chai BX; Tang ZM; Liu XW; Tu M Zhongguo Yao Li Xue Bao; 1999 Apr; 20(4):371-4. PubMed ID: 10452128 [TBL] [Abstract][Full Text] [Related]
6. Mediation of anorexia by human recombinant tumor necrosis factor through a peripheral action in the rat. Bodnar RJ; Pasternak GW; Mann PE; Paul D; Warren R; Donner DB Cancer Res; 1989 Nov; 49(22):6280-4. PubMed ID: 2804974 [TBL] [Abstract][Full Text] [Related]
7. Tissue distribution, stability, and pharmacokinetics of Apo2 ligand/tumor necrosis factor-related apoptosis-inducing ligand in human colon carcinoma COLO205 tumor-bearing nude mice. Xiang H; Nguyen CB; Kelley SK; Dybdal N; Escandón E Drug Metab Dispos; 2004 Nov; 32(11):1230-8. PubMed ID: 15282212 [TBL] [Abstract][Full Text] [Related]
8. Molecular design of hybrid tumor necrosis factor-alpha III: polyethylene glycol-modified tumor necrosis factor-alpha has markedly enhanced antitumor potency due to longer plasma half-life and higher tumor accumulation. Tsutsumi Y; Kihira T; Tsunoda S; Kamada H; Nakagawa S; Kaneda Y; Kanamori T; Mayumi T J Pharmacol Exp Ther; 1996 Sep; 278(3):1006-11. PubMed ID: 8819479 [TBL] [Abstract][Full Text] [Related]
9. Clearance of recombinant tissue factor pathway inhibitor (TFPI) in rabbits. Palmier MO; Hall LJ; Reisch CM; Baldwin MK; Wilson AG; Wun TC Thromb Haemost; 1992 Jul; 68(1):33-6. PubMed ID: 1514170 [TBL] [Abstract][Full Text] [Related]
10. Pharmacokinetics of recombinant human tumor necrosis factor alpha in rhesus monkeys after intravenous administration. Greischel A; Zahn G J Pharmacol Exp Ther; 1989 Oct; 251(1):358-61. PubMed ID: 2795465 [TBL] [Abstract][Full Text] [Related]
11. Differential induction of adrenomedullin, interleukins and tumour necrosis factor-alpha by lipopolysaccharide in rat tissues in vivo. Li YY; Wong LY; Cheung BM; Hwang IS; Tang F Clin Exp Pharmacol Physiol; 2005 Dec; 32(12):1110-8. PubMed ID: 16445578 [TBL] [Abstract][Full Text] [Related]
12. Rapid clearance of human insulin-like growth factor binding protein-3 from the rat circulation and cellular localization in liver, kidney and stomach. Arany E; Zabel P; Hill DJ Growth Regul; 1996 Mar; 6(1):32-41. PubMed ID: 8717448 [TBL] [Abstract][Full Text] [Related]
13. Plasma clearance of human extracellular-superoxide dismutase C in rabbits. Karlsson K; Marklund SL J Clin Invest; 1988 Sep; 82(3):762-6. PubMed ID: 3417870 [TBL] [Abstract][Full Text] [Related]
14. The tissue distribution of tumor necrosis factor-alpha in rats: a compartmental model. Keith M; Norwich KH; Wong W; Jeejeebhoy KN Metabolism; 2000 Oct; 49(10):1309-17. PubMed ID: 11079821 [TBL] [Abstract][Full Text] [Related]
15. Comparative tissue distribution of 125I- and U-14C-labeled recombinant human interleukin-2 in the rat. Sabo J; Ni G; Nadeau R; Liberato DJ; Loh A Lymphokine Cytokine Res; 1992 Aug; 11(4):229-33. PubMed ID: 1420601 [TBL] [Abstract][Full Text] [Related]
16. 99mTc-labeling and in vitro and in vivo evaluation of HYNIC- and (Nalpha-His)acetic acid-modified [D-Glu1]-minigastrin. von Guggenberg E; Behe M; Behr TM; Saurer M; Seppi T; Decristoforo C Bioconjug Chem; 2004; 15(4):864-71. PubMed ID: 15264875 [TBL] [Abstract][Full Text] [Related]
17. Kinetics of receptor-mediated uptake and processing of interferon-alpha 2a and tumor necrosis factor-alpha by human tumor cells. Dunne SL; Bajzer Z; Vuk-Pavlović S Growth Factors; 1990; 2(2-3):167-77. PubMed ID: 2160259 [TBL] [Abstract][Full Text] [Related]
18. Characterization of the antitumor activities of human tumor necrosis factor-alpha and the comparison with other cytokines: induction of tumor-specific immunity. Palladino MA; Shalaby MR; Kramer SM; Ferraiolo BL; Baughman RA; Deleo AB; Crase D; Marafino B; Aggarwal BB; Figari IS J Immunol; 1987 Jun; 138(11):4023-32. PubMed ID: 3295044 [TBL] [Abstract][Full Text] [Related]
19. Tumor necrosis factor-alpha alters phospholipid content in the bronchoalveolar lavage-accessible space of isolated perfused rat lungs. Hertzog JH; Godinez MH; Godinez RI Crit Care Med; 1994 Dec; 22(12):1969-75. PubMed ID: 7988135 [TBL] [Abstract][Full Text] [Related]
20. Evaluation of an internalizing monoclonal antibody labeled using N-succinimidyl 3-[131I]iodo-4-phosphonomethylbenzoate ([131I]SIPMB), a negatively charged substituent bearing acylation agent. Shankar S; Vaidyanathan G; Affleck DJ; Peixoto K; Bigner DD; Zalutsky MR Nucl Med Biol; 2004 Oct; 31(7):909-19. PubMed ID: 15464393 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]